natgillin/translations-raw huggingface dataset:
(p-værdi < 0,0001)
(p-value < 0.0001)
Effektresultater fra studie E3200
Table 8 Efficacy results for trial E3200
Studiet var et åbent, randomiseret, aktivt kontrolleret, klinisk fase II-studie, som undersøgte Avastin i kombination med 5-FU/FA som 1.-linjebehandling af metastatisk kolorektalkræft.
This was a phase II randomised, active-controlled, open-labelled clinical trial investigating Avastin in combination with 5-FU/FA as first-line treatment of metastatic colorectal cancer.
Studie MO22224 evaluerede bevacizumabs virkning og sikkerhed i kombination med kemoterapi til platinresistent, recidiverende epitelial ovariecancer, tubacancer og primær peritonealcancer.
Study MO22224 evaluated the efficacy and safety of bevacizumab in combination with chemotherapy for platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Nyrer og urinveje
Dyspnoea, Rhinitis
Den samlede seponeringsfrekvens på grund af bivirkninger var 8,8 % i kemoterapi-armen og 43,6 % i kemoterapi + bevacizumab-armen (hovedsagelig på grund af bivirkninger af grad 2-3).
The overall rates of discontinuation due to adverse events were 8.8% in the CT arm and 43.6% in the CT + BV arm (mostly due to Grade 2-3 adverse events) and the median time to discontinuation in the CT + BV arm was 5.2 months compared with 2.4 months in the CT arm.
4.4 og Proteinuri i pkt.
For further information on proteinuria see section 4.4 and Proteinuria in section 4.8.
Sårhelingskomplikationerb,d
Wound healing complicationsb,d,
I to efterfølgende studier hos patienter med behandlede hjernemetastaser (som inkluderede omkring 800 patienter) blev der ved sikkerheds-interimanalysen rapporteret om grad 2
In two subsequent studies in patients with treated brain metastases (which included around 800 patients), one case of Grade 2 CNS haemorrhage was reported in 83 subjects treated with bevacizumab (1.2%) at the time of interim safety analysis (NCI-CTCAE v.3).
Risikoen for at udvikle en rørformet forbindelse (fistel) mellem skeden og et eller andet sted på tarmen kan øges, hvis du har vedvarende livmoderhalskræft, hvis livmoderhalskræften er kommet igen, eller hvis livmoderhalskræften har spredt sig.
The risk of developing connections between the vagina and any parts of the gut can increase if you have persistent, recurrent or metastatic cervical cancer.
S amlet res pons rate Rate (n) p-værdi
Rate (n) p-value
I FOLFOX undergruppen var den mediane PFS 8,6 måneder i placebogruppen vs 9,4 måneder for bevacizumab-behandlede patienter, HR = 0,89, 97,5 % konfidensinterval = [0,73-1,08]; p-værdi = 0,1871.
In the FOLFOX treatment subgroup, the median PFS was 8.6 months in placebo and 9.4 months in bevacizumab treated patients, HR = 0.89, 97.5% CI = [0.73; 1.08]; p-value = 0.1871, the corresponding results in the XELOX treatment subgroup being 7.4 vs. 9.3 months, HR = 0.77, 97.5% CI = [0.63; 0.94]; p-value = 0.0026.
Samlet overlevelse - Primær analyse Hazard ratio (95% konfidensinterval)
Overall survival - Primary analysis1 Hazard Ratio (95% CI)
Avastin vil blive givet sammen med kemoterapibehandling, der indeholder platin.
Avastin will be administered together with a chemotherapy regimen containing platinum.
Patienter og procentdel af patienter med det bedste objektive respons bekræftet komplet respons eller partielt respons; procent beregnet på grundlag af patienter med målbar sygdom ved baseline 95 % konfidensinterval for one sample binomial ved brug af Pearson-Clopper metoden Ca. 95 % konfidensinterval for forskel mellem to rater ved brug af Hauck-Anderson metoden log-rank-tes t (s tratificeret)
3 95% CI for one sample binomial using Pearson-Clopper method Approximate 95% CI for difference of two rates using Hauck-Anderson method 5 log-rank test (stratified)
4.4) Brugen af Avastin er blevet forbundet med alvorlige tilfælde af fistler, herunder også letale tilfælde.
Non-GI Fistulae (see section 4.4) Avastin use has been associated with serious cases of fistulae including reactions resulting in death.
(14,9 vs 11,9 måneder; p = 0,1061)
(14.9 vs. 11.9 months; p = 0.1061)
Hvis den tåles godt, vil den næste infusion vare 60 minutter.
If this is well-tolerated the second infusion may be given over 60 minutes.
Leucovorin 200 mg/m2 i.v.
Leucovorin 200 mg/m2 IV 2 h 5-Fluorouracil
• tilstopning af meget små blodårer i nyrerne,
• clogging of a very small blood vessel(s) in the kidney,
Der er ikke foretaget studier for at undersøge bevacizumabs farmakokinetik hos patienter med nedsat leverfunktion, idet metabolismen og udskillelsen af bevacizumab i det væsentlige ikke finder sted i leveren.
No trials have been conducted to investigate the pharmacokinetics of bevacizumab in patients with hepatic impairment since the liver is not a major organ for bevacizumab metabolism or excretion.
Indgivelsesmetode og indgivelsesvej
Method and route of administration
Effektresultater fra studie BO17704
Table 13 Efficacy results for trial BO17704
Forskel i responsrate 95 % konfidensinterval for forskel på responsrate4 P (Chi2 test)
Difference in Response Rates 95% CI for Difference in Response Rates4
(14,9 vs 17,5 måneder; p = 0,4146)
(14.9 vs. 17.5 months; p = 0.4146)
1Endelig analyse 2Tumorvurdering og responsevaluering var bestemt af investigatorerne udfra GOG RECIST kriterier (revideret RECIST guideline (version 1.1) Eur J Cancer.
RECIST criteria (Revised RECIST guideline (version 1.1).
• MO22224 evaluerede bevacizumabs virkning og sikkerhed i kombination med paclitaxel, topotecan eller pegyleret liposomal doxorubicin hos patienter med platinresistent, recidiverende epitelial ovariecancer, tubacancer eller primær peritonealcancer.
• MO22224 evaluated the efficacy and safety of bevacizumab in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin in patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Disse blodkar forsyner tumoren med næringsstoffer og ilt.
The VEGF protein causes blood vessels to grow within tumours, these blood vessels provide the tumour with nutrients and oxygen.
Kemoterapi (n=182)
CT (n=182)
Den mediane, samlede overlevelse var 20,3 måneder for placebogruppen vs 21,2 måneder for bevacizumab-behandlede patienter i FOLFOX undergruppen, HR = 0,94, 97,5 % konfidensinterval = [0,75-1,16]; p-værdi = 0,4937.
The median overall survival was 20.3 months in placebo and 21.2 months in bevacizumab treated patients in the FOLFOX treatment subgroup, HR=0.94, 97.5% CI = [0.75; 1.16]; p-value = 0.4937, the corresponding results in the XELOX, treatment subgroup being 19.2 vs. 21.4 months, HR = 0.84, 97.5% CI = [0.68; 1.04]; p-value = 0.0698.
• smerter, inklusive hovedpine, rygsmerter, bækkensmerter og smerter omkring endetarmen,
• pain, including headache, back pain and pain in the pelvis and anal regions,
Der er ikke foretaget studier for at undersøge bevacizumabs farmakokinetik hos patienter med nedsat nyrefunktion, idet metabolismen og udskillelsen af bevacizumab i det væsentlige ikke finder sted i nyrerne.
No trials have been conducted to investigate the pharmacokinetics of bevacizumab in renally impaired patients since the kidneys are not a major organ for bevacizumab metabolism or excretion.
Effektresultater for studiet er vist i tabel 14.
The efficacy results of the study are presented in Table 14.
Nogle af bivirkningerne er almindelige ved behandling med kemoterapi, men Avastin kan forværre disse bivirkninger, når det gives i kombination med kemoterapi, f.eks. palmoplantar erytrodysæstesisyndrom med pegyleret liposomal doxorubicin eller capecitabin, perifer sensorisk neuropati med paclitaxel eller oxaliplatin, negleproblemer og alopeci med paclitaxel og paronykie med erlotinib.
Examples include palmar-plantar erythrodysaesthesia syndrome with pegylated liposomal doxorubicin or capecitabine, peripheral sensory neuropathy with paclitaxel or oxaliplatin, nail disorders or alopecia with paclitaxel, and paronychia with erlotinib.
Avastin kan nedsætte kvinders frugtbarhed.
Avastin may impair female fertility.
Det primære endepunkt var samlet overlevelse.
The primary efficacy endpoint was overall survival.
Trombo emboli (venøs)b
Thromboembolism (venous)
Osteonekrose af kæbenb,c
Osteonecrosis of the jaw b,c
Kemoterapi + Avastin (n=227)
Chemotherapy + Avastin (n=227)
I begge behandlingsarme var der ingen bivirkninger som resulterede i dødsfald.
No AEs leading to death occurred in either treatment arm; all deaths were attributed to disease progression.
Sammenlignet med 5-FU/FA-kemoterapi alene medførte tillæg af Avastin 5 mg/kg hver 2. uge til 5-FU/FV en højere, objektive responsrater, signifikant længere progressionsfri overlevelse og en tendens til længere overlevelse.
The addition of Avastin 5 mg/kg every two weeks to 5-FU/FA resulted in higher objective response rates, significantly longer progression-free survival, and a trend in longer survival as compared to 5-FU/FA chemotherapy alone.
hver 2. uge (eller bevacizumab 15 mg/kg hver 3. uge, hvis det anvendes i kombination med topotecan 1,25 mg/m2 på dag 1-5 hver 3. uge).
• The chosen chemotherapy was combined with bevacizumab 10 mg/kg IV every 2 weeks (or bevacizumab 15 mg/kg every 3 weeks if used in combination with topotecan 1.25 mg/m2 on Days 1-5 every 3 weeks).
Hvert 4 ml hætteglas indeholder 100 mg bevacizumab svarende til 1,4 mg/ml efter foreskreven fortynding.
Each 4 ml vial contains 100 mg of bevacizumab, corresponding to 1.4 mg/ml when diluted as recommended.
Ikkemandibulær osteonekrosea,f
Osteonecrosis of the jawa,b Non-mandibular osteonecrosisa,f
Effektresultater fra studie E4599
Table 12 Efficacy results for trial E4599
Det primære endepunkt for studiet var progressionsfri overlevelse (PFS) baseret på investigators vurdering.
The primary endpoint was progression-free survival (PFS) based on independent review assessment.
(17,5 vs 14,3 måneder; p = 0,0609)
(17.5 vs.14.3 months; p = 0.0609)
• blokering af arterier på grund af en blodprop,
• blocking of the arteries by a blood clot,
• næseblod,
• nose bleed,
Objektiv responsrate
Objective response rate
• Den primære analyse af investigatorvurderet PFS (censureret for CA-125-progressioner og NPT) viser en stratificeret hazard ratio på 0,62 (95 % konfidensinterval: 0,52-0,75, ensidig logrank p-værdi < 0,0001), når CPB15+ sammenlignes med CPP, med en median PFS på 12,0 måneder i CPP-armen og 18,2 måneder i CPB15+-armen.
• The primary analysis of investigator-assessed PFS (censoring for CA-125 progressions and NPT) shows a stratified hazard ratio of 0.62 (95% CI: 0.52-0.75, 1-sided log-rank p-value < 0.0001) when CPB15+ is compared with CPP, with a median PFS of 12.0 months in the CPP arm and 18.2 months in the CPB15+ arm.
Når lægemidlet anvendes til voksne patienter med fremskreden kræft i æggestokkene, kræft i æggelederne eller primær bughindekræft, hvor sygdommen er kommet igen mere end 6 måneder efter sidste kemoterapi, som indeholdt platin, vil Avastin blive givet sammen med carboplatin og gemcitabin eller sammen med carboplatin og paclitaxel.
When used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back at least 6 months after the last time they were treated with a chemotherapy regimen containing a platinum agent, Avastin will be administered in combination with carboplatin and gemcitabine or with carboplatin and paclitaxel.
Infektion Urinvejsinfektion
Infection, Urinary tract infection
Randomiserede patienter med stadie III sub-optimalt tumorreduceret sygdom3
Randomised patients with stage III suboptimally debulked disease3
• Analysen af PFS vurderet af en uafhængig evalueringskomité (censureret for NPT) viser en stratificeret hazard ratio på 0,62 (95 % konfidensinterval: 0,50-0,77, ensidig log-rank p-værdi < 0,0001), når CPB15+ sammenlignes med CPP, med en median PFS på 13,1 måned i CPP-armen og 19,1 måned i CPB15+-armen.
• The analysis of PFS as determined by the independent review committee (censoring for NPT) shows a stratified hazard ratio of 0.62 (95% CI: 0.50-0.77, 1-sided log-rank p-value < 0.0001) when CPB15+ is compared with CPP, with a median PFS of 13.1 in the CPP arm and 19.1 months in the CPB15+ arm.
Andre bivirkninger ved behandling med Avastin, der blev set med en højere frekvens hos patienter over 65 år versus patienter ≤ 65 år, var grad 3-4 leukopeni og trombocytopeni (NCI-CTCAE v. 3) samt neutropeni (alle grader), diarré, kvalme, hovedpine og træthed (se pkt.
Other reactions with a higher frequency seen in patients over 65 were Grade 3-4 leucopenia and thrombocytopenia (NCI-CTCAE v.3); and all Grade neutropenia, diarrhoea, nausea, headache and fatigue as compared to those aged ≤ 65 years when treated with Avastin (see sections 4.4 and 4.8 under Thromboembolism).
Hazard ratio vs placebo-arm (95 % konfidensinterval)
Hazard ratio vs placebo arm (95% CI) p-value
Tabel 25: Effektresultater fra studie GOG-0240 for Avastinbehandling Kemoterapi (n=225)
Table 25 Efficacy results from study GOG-0240 by Avastin Treatment
En stor del af patienterne (ca. 63 % IFN/placebo; 55 % Avastin/IFN) fik forskellige ikke-specificerede cancerbehandlinger efter studiets ophør, inklusive antineoplastiske lægemidler, som kan have haft indvirkning på analysen af den samlede overlevelse.
Avastin/IFN) received a variety of non-specified post-trial anti-cancer therapies, including antineoplastic agents, which may have impacted the analysis of overall survival.
Når lægemidlet anvendes til voksne patienter med fremskreden kræft i æggestokkene, kræft i æggeledere eller primær bughindekræft, hvor sygdommen er kommet igen tidligere end 6 måneder efter sidste kemoterapi, som indeholdt platin, vil Avastin blive givet sammen med paclitaxel eller topotecan eller pegyleret liposomal doxorubicin.
When used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back before 6 months after the last time they were treated with a chemotherapy regimen containing a platinum agent, Avastin will be administered in combination with paclitaxel, or topotecan, or pegylated liposomal doxorubicin.
• Median PFS-øgning på 2,9 måneder, hazard ratio 0,69 (p = 0,0002, 95 % konfidensinterval 0,56-0,84)
• Study AVF3694g (capecitabine) • Median PFS increase 2.9 months, HR 0.69 (p = 0.0002, 95% CI 0.56; 0.84)
Patienter med tromboemboliske bivirkninger ≤ grad 3 (NCI-CTCAE v. 3) skal monitoreres nøje.
need to be closely monitored (NCI-CTCAE v.3).
Resultaterne af dette studie vises i tabel 10.
The results of this trial are presented in Table 10.
a patienter med målbar sygdom ved baseline Samlet overlevelse Median (måneder)
a patients with measurable disease at baseline Overall survival
4.4) Der har været sjældne rapporter om symptomer, der stemmer overens med PRES, en sjælden neurologisk forstyrrelse, hos Avastinbehandlede patienter.
Posterior Reversible Encephalopathy Syndrome (see section 4.4) There have been rare reports of Avastin-treated patients developing signs and symptoms that are consistent with PRES, a rare neurological disorder.
Rektalblødning Stomatitis Obstipation Diarré Kvalme Opkastning Abdominalsmerter
Rectal haemorrhage, Stomatitis, Constipation, Diarrhoea, Nausea, Vomiting, Abdominal pain
Behandling af platinfølsom recidiverende sygdom: Avastin administreres enten sammen med carboplatin og gemcitabin i 6 og op til 10 behandlingsserier eller sammen med carboplatin og paclitaxel i 6 og op til 8 behandlingsserier, efterfulgt af fortsat behandling med Avastin som monoterapi indtil sygdomsprogression.
Treatment of platinum-sensitive recurrent disease: Avastin is administered in combination with either carboplatin and gemcitabine for 6 cycles and up to 10 cycles or in combination with carboplatin and paclitaxel for 6 cycles and up to 8 cycles, followed by continued use of Avastin as single agent until disease progression.The recommended dose of Avastin is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.
% patienter med objektivt respons p-value
% pts with objective response p-value
Antal patienter Samlet overlevelse Median tid (måneder) 95 % konfidensinterval Hazard ratioc p-værdi
Number of patients Overall survival Median time (months) 95% CI Hazard ratioc p-value
Hazard ratio (95% konfidensinterval)
Hazard ratio (95% confidence interval)
Det primære endepunkt for studiet var samlet overlevelse, og de sekundære endepunkter var bl.a. progressionsfri overlevelse.
The primary endpoint was overall survival, with secondary endpoints for the trial including progression-free survival.
Den anbefalede dosis af Avastin, når det anvendes sammen med erlotinib, er 15 mg/kg legemsvægt en gang hver 3. uge som intravenøs infusion.
The recommended dose of Avastin when used in addition to erlotinib is 15 mg/kg of body weight given once every 3 weeks as an intravenous infusion.
• AVF4095g evaluerede bevacizumabs virkning og sikkerhed i kombination med carboplatin og gemcitabin, efterfulgt af bevacizumab som monoterapi, hos patienter med platinfølsom, recidiverende epitelial ovariecancer, tubacancer eller primær peritonealcancer.
• AVF4095g evaluated the efficacy and safety of bevacizumab in combination with carboplatin and gemcitabine, followed by bevacizumab as a single agent in patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Primær endepunkt
Primary Endpoint
Arteriel tromboemboli (se pkt.
Arterial thromboembolism (see section 4.8)
Avastin bruges også hos voksne til behandling af fremskreden kræft i æggestokkene, kræft i æggeledere eller primær bughindekræft.
Avastin is also used for the treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
c Baseret på et substudie fra NSABP C-08 med 295 patienter.
Based on a substudy from NSABP C-08 with 295 patients d For additional information refer below within section "Further information on selected serious adverse reactions."
Bevacizumab er, i kombination med platinbaseret kemoterapi, indiceret til 1.-linjebehandling af voksne patienter med ikke-operabel fremskreden, metastatisk eller recidiverende, ikke-småcellet lungekræft.
Bevacizumab, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.
69 % af patienterne i de 2 behandlingsarme havde serøs histologisk type af adenokarcinom.
The incidence of each histologic sub-type of EOC was similar between the treatment arms; 69% of patients in each treatment arm had serous adenocarcinoma histologic type.
• Carboplatin (AUC4, dag 1) og gemcitabin (1.000 mg/m2 på dag 1 og 8) samtidig med placebo hver 3. uge i 6 og op til 10 behandlingsserier, efterfulgt af placebo (hver 3. uge) som monoterapi indtil sygdomsprogresssion eller uacceptabel toksicitet.
A total of 484 patients with measurable disease were randomised 1:1 to either: • Carboplatin (AUC4, Day 1) and gemcitabine (1000 mg/m2 on Days 1 and 8) and concurrent placebo every 3 weeks for 6 and up to 10 cycles followed by placebo (every 3 weeks) alone until disease progression or unacceptable toxicity
Hvert 16 ml hætteglas indeholder 400 mg bevacizumab svarende til 16,5 mg/ml efter foreskreven fortynding.
Each 16 ml vial contains 400 mg of bevacizumab, corresponding to 16.5 mg/ml when diluted as recommended
Progressionsfri overlevelse Median tid (måneder) Hazard ratio p-værdi
Progression-free survival Median time (months) Hazard ratio p-value
Ved forskellige indikationer er der set fistler, der involverer andre dele af kroppen end mavetarmkanalen (f.eks. bronkopleurale og biliære fistler).
Uncommon (≥ 0.1% to < 1%) reports of fistulae that involve areas of the body other than the gastrointestinal tract (e.g. bronchopleural and biliary fistulae) were observed across various indications.
I et klinisk studie hos patienter med persisterende, recidiverende eller metastatisk cervixcancer (studie GOG-0240) blev infektioner af grad 3-5 rapporteret hos op til 24 % af patienterne, behandlet med Avastin i kombination med paclitaxel og topotecan, sammenlignet med hos op til 13 % af patienterne, behandlet med paclitaxel og topotecan.
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG0240), grade 3-5 infections have been reported in up to 24% of patients treated with Avastin in combination with paclitaxel and topotecan compared with up to 13% of patients treated with paclitaxel and topotecan.
(p-værdi = 0,00004)
(p-value = 0.00004)
I et klinisk studie hos patienter med persisterende, recidiverende eller metastatisk cervixcancer (studie GOG-0240) blev blødninger af grad 3-5 rapporteret hos op til 8,3 % af patienterne, som blev behandlet med Avastin i kombination med paclitaxel og topotecan, sammenlignet med hos op til 4,6 % af patienterne, som blev behandlet med paclitaxel og topotecan.
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG0240), grade 3-5 bleeding reactions have been reported in up to 8.3% of patients treated with Avastin in combination with paclitaxel and topotecan compared with up to 4.6% of patients treated with paclitaxel and topotecan.
I et klinisk studie hos patienter med persisterende, recidiverende eller metastatisk cervixcancer (studie GOG-0240) blev venøs tromboemboli af grad 3-5 rapporteret hos op til 15,6 % af patienterne, som blev behandlet med Avastin i kombination med paclitaxel og cisplatin, sammenlignet med hos op til 7,0 % af patienterne, som blev behandlet med paclitaxel og cisplatin.
From a clinical trial in patients with persistent, recurrent, or metastatic cervical cancer (study GOG0240), grade 3-5 venous thromboembolic events have been reported in up to 15.6% of patients treated with Avastin in combination with paclitaxel and cisplatin compared with up to 7.0% of patients treated with paclitaxel and cisplatin.
I studie BO25041 blev Avastin føjet til post-operativ strålebehandling med samtidig adjuverende temozolomidbehandling hos pædiatriske patienter med nyligt diagnosticeret supratentorielt, infratentorielt, cerebellært eller pedunkulært høj-grads-gliom.
In study BO25041 of Avastin added to postoperative radiation therapy (RT) with concomitant and adjuvant temozolomide in paediatric patients with newly diagnosed supratentorial, infratentorial, cerebellar, or peduncular high-grade glioma, the safety profile was comparable with that observed in other tumour types in adults treated with Avastin.
1 Hos patienter med målbar sygdom ved baseline.
5 Patients with measurable disease at baseline.
• CPP-arm: Fem serier af placebo (startende i serie 2) i kombination med carboplatin (AUC 6) og paclitaxel (175 mg/m2) i 6 serier, efterfulgt af placebo alene, i op til sammenlagt 15 måneders behandling
• CPP arm: Five cycles of placebo (started cycle 2) in combination with carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles followed by placebo alone, for a total of up to 15 months of therapy
• søvnighed,
• sleepiness,
• nedsat antal af celler i blodet, inklusive hvide blodlegemer som hjælper med at bekæmpe infektioner i kroppen (kan være ledsaget af feber) og celler, der hjælper blodet med at størkne,
• decreased number of cells in the blood, including white cells that help to fight against infections
6.6. for anbefaling om fortynding og anden håndtering.
For dilution and other handling recommendations, see section 6.6.
Fistlera,b Myalgi Artralgi Muskelsvaghed Rygsmerter
Myalgia, Arthralgia, Muscular weakness, Back Pain
(p-værdi = 0,0062)
(p-value = 0.0062)
• blokering af blodårerne i lungerne på grund af en blodprop,
• blocking of the blood vessels of the lungs by a blood clot,
Hvert 4 ml hætteglas indeholder 100 mg bevacizumab.
Each 4 ml vial contains 100 mg of bevacizumab.
Antallet af infusioner, som du skal have, afhænger af, hvordan du reagerer på behandlingen.
The number of infusions that you receive will depend on how you are responding to treatment; you should continue to receive this medicine until Avastin fails to stop your tumour growing.
Proteinuri (se pkt.
Proteinuria (see section 4.8)